Literature DB >> 7864736

Afterword: bottom-line status report: CAN current trends in membrane gas transfer technology lead to an implantable intrathoracic artificial lung?

J D Mortensen1.   

Abstract

For at least 170 years, attempts have been made to alleviate inadequate gas exchange of patients with respiratory failure. Major milestones in the struggle to assist failing natural lungs to achieve adequate blood gas exchange include utilization of oxygen inhalation therapy, mechanical ventilatory assistance, and development of both extracorporeal and intracorporeal mechanical blood gas exchangers. Current state-of-the-art technology related to mechanical membrane blood gas exchangers has produced highly efficient gas transfer membranes and designs capable of replacing all the gas transfer functions of the natural lungs by a mechanical oxygenator-CO2 remover that can fit into a unilateral thoracic cavity. The possibility thus exists of moving extracorporeal mechanical blood oxygenators into the body as an implantable intracorporeal artificial lung. Problems impeding the development of an implantable, intrathoracic artificial lung have been identified, and at least partially successful attempts to solve them have been reported. The conclusion drawn is that the appropriate answer to the question posed in the title of this communication is affirmative. Reasons for this conclusion include the persistent widespread major need for better relief from respiratory failure, the advanced state-of-the-art of mechanical blood gas exchanger technology, and the incompletely tapped ingenuity of the human mind.

Entities:  

Mesh:

Year:  1994        PMID: 7864736     DOI: 10.1111/j.1525-1594.1994.tb03335.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  1 in total

1.  Hemodynamic effects of pumpless extracorporeal membrane oxygenation (ECMO) support for chronically pressure-overloaded right heart failure in a canine experimental model.

Authors:  Kiyokazu Tamesue; Sugato Nawa; Shingo Ichiba; Motoi Aoe; Hiroshi Date; Nobuyoshi Shimizu
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.